Lysostaphin Lysibody Leads to Effective Opsonization and Killing of Methicillin-Resistant Staphylococcus aureus in a Murine Model

@article{Raz2018LysostaphinLL,
  title={Lysostaphin Lysibody Leads to Effective Opsonization and Killing of Methicillin-Resistant Staphylococcus aureus in a Murine Model},
  author={Assaf Raz and Anna Claudia Marques Serrano and Maneesha Thaker and Tricia Alston and Vincent A. Fischetti},
  journal={Antimicrobial Agents and Chemotherapy},
  year={2018},
  volume={62}
}
The cell wall of Gram-positive bacteria contains abundant surface-exposed carbohydrate structures that are highly conserved. While these properties make surface carbohydrates ideal targets for immunotherapy, carbohydrates elicit a poor immune response that results primarily in low-affinity IgM antibodies. ABSTRACT The cell wall of Gram-positive bacteria contains abundant surface-exposed carbohydrate structures that are highly conserved. While these properties make surface carbohydrates ideal… 
Two site recognition of Staphylococcus aureus peptidoglycan by lysostaphin SH3b
TLDR
The molecular mechanism underpinning recognition of staphylococcal peptidoglycan by the lysostaphin SH3b domain is elucidated and it is proposed that this unusual binding mechanism allows synergistic and structurally dynamic recognition of S. aureus peptide stem and underpins the potent bacteriolytic activity of this enzyme.
Reducing Staphylococcus aureus resistance to lysostaphin using CRISPR‐dCas9
TLDR
It is shown that Staphylococcus aureus, a human and animal pathogen, while susceptible to the potent staphylolytic enzyme lysostaphin (Lst) in buffered saline, is highly resistant in the rich medium tryptic soy broth (TSB).
Therapeutic applications of lysostaphin against <fi>Staphylococcus aureus</fi>
TLDR
This review provides an overview of the therapeutic applications of native and engineered lysostaphin derivatives developed to eradicate S. aureus infections and outlines the needs for highly effective anti-staphylococcal agents.
Therapeutic applications of lysostaphin against Staphylococcus aureus
TLDR
This review provides an overview of the therapeutic applications of native and engineered lysostaphin derivatives developed to eradicate S. aureus infections.
Bacteriophage Proteome: Insights and Potentials of an Alternate to Antibiotics
TLDR
The hidden potential of bacteriophage proteins may be a practical alternative approach to manage the threat of antibiotic resistance, according to an integrated viewpoint that aims to decipher the insights and abilities of bacter iophages and their derived proteins as potential alternatives to antibiotics.
Staphylococcins: an update on antimicrobial peptides produced by staphylococci and their diverse potential applications.
TLDR
An overview of the current knowledge on staphylococcins will be presented with emphasis on the information collected in the last decade, including a brief description of new peptides, which exhibit potential biotechnological applications.
Staphylococcins: an update on antimicrobial peptides produced by staphylococci and their diverse potential applications.
TLDR
An overview of the current knowledge on staphylococcins will be presented with emphasis on the information collected in the last decade, including a brief description of new peptides.
Protective Effect of the Golden Staphyloxanthin Biosynthesis Pathway on Staphylococcus aureus under Cold Atmospheric Plasma Treatment
TLDR
The data demonstrated that the yellow pigment intermediates of the staphyloxanthin biosynthetic pathway are responsible for the protection of S. aureus from CAP inactivation, and the key enzymes, such as CrtM and CrtN, of the golden staphylloxanth inactivated pathway could be important targets for the design of novel sterilization strategies against S.Aureus infections.
...
...

References

SHOWING 1-10 OF 78 REFERENCES
Bacteriophage lysins as effective antibacterials.
Lysostaphin: A Staphylococcal Bacteriolysin with Potential Clinical Applications
TLDR
In vitro and in vivo studies performed with lysostaphin have shown that thisStaphylococcin has potential to be used, solely or in combination with other antibacterial agents, to prevent or treat bacterial staphylococcal infectious diseases.
Disarming Staphylococcus aureus from destroying human cells by simultaneously neutralizing six cytotoxins with two human monoclonal antibodies
TLDR
It is concluded that simultaneous inhibition of alpha-hemolysin and five leukocidins by ASN100 blocks cytolytic activity of S. aureus towards human target cells in vitro.
Lack of wall teichoic acids in Staphylococcus aureus leads to reduced interactions with endothelial cells and to attenuated virulence in a rabbit model of endocarditis.
TLDR
It is concluded that WTA is an important factor in the induction and progression of endovascular S. aureus infection, likely through a specific interaction with endothelial cells.
Lysostaphin Treatment of Experimental Methicillin-Resistant Staphylococcus aureus Aortic Valve Endocarditis
TLDR
It is concluded that lysostaphin given alone or in combination with vancomycin is more effective in the treatment of experimental methicillin-resistant S. aureus aortic valve endocarditis than vancomYcin alone.
Profiling the surfacome of Staphylococcus aureus
TLDR
Results show for the first time that the cell surface of different S. aureus strains is not only highly variable, but also that the displayed proteins are very heterogeneous.
Immunity to lysostaphin and its therapeutic value for ocular MRSA infections in the rabbit.
TLDR
Lysostaphin treatment of immunized rabbits was effective in treating S. aureus-infected eyes, despite the presence of anti-lysostAPHin antibody.
Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells
TLDR
This standardized assay, in combination with the standardized ELISA, can be used to evaluate current and developing pneumococcal vaccines, in which functional opsonophagocytic antibody activity may correlate with protection against pneumococCal disease.
The Recombinant Phage Lysin LysK Has a Broad Spectrum of Lytic Activity against Clinically Relevant Staphylococci, Including Methicillin-Resistant Staphylococcus aureus
TLDR
Lactococcal lysates containing recombinant LysK were found to inhibit a range of different species of staphylococci isolated from bovine and human infection sources, including methicillin-resistant Staphylitis aureus.
...
...